Free 1-hr "Live" CME/AAPA/CNE/CPE/CPT/CPH Webinar on FDA's Bad Ad Program - Drug Information Update

DDI Webinar - Bad Ad 5/19/20

FDA’s Division of Drug Information is presenting a series of continuing education webinars targeting the needs of all health care professionals.

FDA Drug Topics: FDA’s Bad Ad Program   Will be held on:   May 19, 2020   Time:  1:00 pm to 2:00 pm (EST)   To register for the online meeting, please visit:  https://collaboration.fda.gov/ddi051920/event/registration.html   After registering, you will receive a calendar invitation with details on how to join the online meeting.

Activity Outline Description: This series of educational webinars is designed to aid physicians, physician assistants, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students, to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety. There are a number of innovative opportunities to collaborate with the FDA. This webinar will focus on the FDA's Bad Ad Program. It will provide an overview of prescription drug promotion and its regulation along with information on how health care professionals can report potentially false or misleading prescription drug promotion to the FDA. References: The reference below is to support the claim in the speaker’s presentation that states, “In fact, the pharmaceutical industry spent more than $24 billion on drug promotion in 2017, with more than $18.5 billion allotted for marketing to HCPs.” Kantar Media. Syneos Health™ PromotionalAnswers. Data on file (2018). U.S. Food and Drug Administration. (2020). Truthful Prescription Drug Advertising and Promotion: https://www.fda.gov/drugs/office-prescription-drug-promotion/truthful-prescription-drug-advertising-and-promotion.   U.S. Food and Drug Administration. (2020). Warning Letters and Notice of Violation Letters to Pharmaceutical Companies: https://www.fda.gov/drugs/enforcement-activities-fda/warning-letters-and-notice-violation-letters-pharmaceutical-companies.  Series Objectives: Explain how to utilize FDA’s drug information, medication safety resources, and regulatory guidance, to improve delivery of patient care and optimize outcomes. Describe and inform health care providers of recent labeling changes which would impact prescribing and medication management to optimize patient care. Learning Objectives: After completion of this activity, the participant will be able to: Discuss FDA's role in regulating prescription drug promotion and advertising. Describe the role that Health Care Professionals (HCPs) can play in protecting the public health by recognizing prescription drug promotion and advertising that is potentially false or misleading. Explain how HCPs can effectively report potentially false or misleading prescription drug promotion to the FDA through the Bad Ad Program. Target Audience: This activity is intended for physicians, physician assistants, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students.  Schedule: 1:00 pm - 2:00 pm – FDA Drug Topics: FDA’s Bad Ad Program presented by Melinda McLawhorn, PharmD, MPH, BCPS, RAC, Team Leader in the Office of Prescription Drug Promotion’s (OPDP) Division of Advertising and Promotion-2.

Continuing Education: Accreditation:

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians and physician assistants should claim only the credit commensurate with the extent of their participation in the activity. CPE This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-19-020-L04-P, and ACPE Universal Activity Number JA0002895-0000-19-020-L04-T for 1.00 contact hour(s). CNE FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

AAPA

This activity is designated for 1.00 AAPA Category 1 CME credits. FDA Center for Drug Evaluation and Research has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.

CPH Up to 1.00 CPH Recertification Credits may be earned at this event. Requirements for receiving CE Credit: Physicians, physician assistants, nurses, pharmacists, pharmacy technicians, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation survey via the CE Portal (ceportal.fda.gov). Final activity evaluations must be completed within two weeks after the activity - no exceptions. Pharmacy participants: Pharmacists and pharmacy technicians will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.   Important Note regarding completion of evaluations and receiving credit: Attendees have 14 days from the last day of the activity to log in, attest to your attendance, and complete the required evaluation survey, to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the activity to obtain their CE credit. Disclosure: Faculty: McLawhorn, Melinda, PharmD, MPH, BCPS, RAC, Team Leader, FDA/CDER/OMP/OPDP - nothing to disclose Planning Committee: Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose  Cao, Christian, MPAS, PA-C, Safety Evaluator Team Leader, FDA/CDER/OSE/DPV - nothing to disclose DeFronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose  Kapoor, Rama, MD, Medical Officer, FDA - nothing to disclose  Navin, Lesley, RN, MSN, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose  CE Consultation and Accreditation Team: Thompson, Lisa, MSHA, MBA, CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose Registration Fees and Refunds: Registration is complimentary therefore refunds are not applicable. Please direct your comments or questions via email to DDIWebinars@fda.hhs.gov. To learn more about future dates and registration, please visit: www.fda.gov/DDIWebinars.